NSTK · 01.2026Independent supplement reference

Edition 1.0Updated August 1, 2026

Supplement × Prescription·Evidence index

Melatonin and Rivastigmine: what the published research says

PubMed indexes 2 records that name Melatonin and Rivastigmine together, either in the title or in an interaction, co-administration, or pharmacokinetic context. Each one is listed below with its study design and, where the abstract states one, the authors’ own conclusion, quoted and linked. This page reports that literature. It does not tell you whether to combine them.

Studies listed

Human studies

Reviews & meta-analyses

Published

2025–2026

Read the studies ↓ How we select sources

Read this first

An evidence index, not guidance.

Every statement below is attributed to a named, dated, linked source.

This page lists published research relevant to Melatonin and Rivastigmine. It deliberately does not state whether the combination is safe, whether it interacts, in which direction, at what dose, or how far apart to take them.

A study appearing here is not proof that an interaction exists. Two substances can be named together in a paper that never tested them in combination, and a source listed as background may cover only one of them.
Findings are quoted from each abstract as the authors wrote them. NutriStack has not re-analysed, pooled, or reconciled them, and they may disagree with each other.
NutriStack’s own interaction assessment for this pair is not published here. It has not completed qualified-human clinical review, so it is withheld from search. See the publication gate.
Nothing here is medical advice. Decisions about prescription medication and supplements belong with your prescriber or pharmacist, who can see your full regimen.

The research

2 studies naming Melatonin and Rivastigmine.

Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.

Sex-Dependent Effects of Rivastigmine on Melatonin Receptors in Middle-Aged Rats.

Noro psikiyatri arsivi · 2026 · PMID 41969958

“RIVA treatment in middle-aged rats may cause changes in MT1 and MT2 gene expression concomitant with behavioral alterations. The variation in melatonin receptor expression across sexes indicates a potential sex-dependent impact in aging populations, suggesting an interaction between cholinergic and melatonergic systems.”
Ünal et al. · Authors' conclusion

Names both Melatonin and Rivastigmine in its title.

Exploiting the potential of rivastigmine-melatonin derivatives as multitarget metal-modulating drugs for neurodegenerative diseases.

Journal of inorganic biochemistry · 2025 · PMID 39378762

Human subjects

“The developed RIV-IND hybrids, derived from the conjugation of an approved anti-AD drug, rivastigmine (RIV), with melatonin analogues, namely indole (IND) derivatives, revealed multifunctional properties, by associating the cholinesterase inhibition of the RIV drug with antioxidant activity, biometal (Cu(II), Zn(II), Fe(III)) chelation properties, inhibition of amyloid-β (Aβ) aggregation (self- and Cu-induced) and of monoamine oxidases (MAOs), as well as neuroprotection…”
Dias et al. · From the abstract

Names both Melatonin and Rivastigmine in its title.

Limitations

What this evidence cannot tell you.

Search-based evidence indexes have real limits, and it is worth being explicit about them:

Selection. These records were found by searching PubMed titles and abstracts for both substance names alongside interaction and pharmacokinetic terms. Relevant work that phrases things differently, or is not indexed in PubMed, will be missing.
No effect size. The quoted conclusions are the authors’ words about their own study. We have not extracted effect direction or magnitude, and a single study’s conclusion is not a consensus.
Population mismatch. Findings in healthy volunteers, animals, or a specific patient group may not transfer to you, your dose, or your formulation.
Absence is not safety. Few published studies means the combination is under-studied, which is not the same as established as safe.

NutriStack

Track what you actually take.

NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Melatonin, Rivastigmine, and several hundred other substances.

The checker is a research and organisation tool, not a clinical decision aid, and its per-pair assessments are excluded from search until they pass claim-level review.

Get NutriStack free → Read the methodology

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.